CHARLOTTESVILLE, Va., – AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases, such as Lupus, Psoriasis, Atopic Dermatitis and Scleroderma. Revealed in the peer-reviewed journal Science Advances, the paper details AMPEL’s breakthrough machine learning approach to characterize disease activity from gene expression data obtained …

Richmond medical technology company Tympanogen Inc. has raised $1 million in fresh funding, according to a Securities and Exchange Commission filing. Tympanogen raised the money from 12 investors and said it is seeking to raise up to $2.5 million through debt and other options, according to the March filing. The round includes participation from Williamsburg’s ShockVentures …

Caretaker Medical, a digital health leader in continuous “beat by beat” wireless patient monitoring technologies, announced that it has received FDA 510(k) Clearance for four new continuous hemodynamic parameters, adding cardiac output, stroke volume, heart rate variability, and left ventricular ejection time to its VitalStream™ non-invasive patient monitoring platform. This is the company’s 5th FDA …

Euclid Vision Corp., a global leader in advanced orthokeratology and proactive myopia management initiatives, is pleased to announce its acquisition of Visionary Optics, a specialty scleral contact lens design and distribution pioneer. The acquisition signifies Euclid’s recognition of the value of joining forces with Visionary Optics, the only company in the US that concentrates almost …

Dr. Richard T. Marconi of VCU and Jeff Gallagher, former Virginia Bio CEO, are recognized for their outstanding contributions to the biosciences in the Commonwealth.   Richmond, VA, (April 22) – Every two years, the Virginia Biotechnology Association recognizes individual Virginians for their significant contributions to bioscience and the Virginia biotechnology ecosystem.  This year, Dr. …

Elkton, VA (EndpointNews) – A construction project built around expanding the vaccine manufacturing capabilities at a Merck site in Elkton, VA, has been completed. The upgrades will support the company’s human papillomavirus vaccine, Gardasil 9, once it gains review and approval from regulators. About 150 new jobs have been added to the site, as the …